ArticlePulmonary circulation2025
Global, Regional, and National Burden of Pulmonary Arterial Hypertension Among Women of Childbearing Age, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.
Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global Burden of Pulmonary Arterial Hypertension in Older Adults and Its Causal Association With Body Mass Index.Pulmonary circulation · 2026Article
- Improved cardiac function and quality of life with initial macitentan-tadalafil combination therapy compared to tadalafil alone in pulmonary arterial hypertension.American journal of translational research · 2026Article
- Mindfulness meditation for pulmonary hypertension program development: Acceptability and feasibility of technology-assisted complementary health intervention for symptom self-management.Heart & lung : the journal of critical careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a common condition among women of childbearing age (WCBA) and is associated with adverse outcomes during pregnancy. However, there is currently a lack of studies that provide a detailed epidemiological characterization of this condition. This study aimed to delineate the global burden of pulmonary arterial hypertension (PAH) among women of childbearing age (WCBA) from 1990 to 2021. We utilized the Global Burden of Disease Study 2021 to estimate the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) for PAH among WCBA across 204 countries and territories from 1990 to 2021. Sociodemographic index (SDI) was used to assess the impact of socioeconomic development on PAH burden. In 2021, global estimates revealed 46,630 prevalent cases of PAH, resulting in 8532 new cases, 1777 deaths and 103,151 DALYs. Globally, the age-standardized prevalence, incidence, mortality, and DALY rates for PAH in 2021 stood at 2.35, 0.43, 0.09, and 5.26 per 100,000 population, respectively. In 2021, Switzerland exhibited the highest age-standardized prevalence rate (7.47/100,000). The highest age-standardized incidence rate was observed in Zambia (0.96/100,000). Mauritius reported the highest age-standardized mortality (0.72/100,000) and DALY rates (40.42/100,000), contrasting sharply with Moldova's lowest rates (0.00/100,000 and 0.51/100,000, respectively). At the regional level, the relationship between the SDI and age-standardized prevalence rates for PAH exhibited an approximate V-shaped pattern. The systematic analysis of PAH burden among WCBA underscores the disease's significant global impact and the necessity for continued research and tailored public health strategies, calling for enhanced awareness, improved diagnostics, and more effective treatment modalities, particularly in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.